Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Antonio Gómez-Outes, M Luisa Suárez-Gea, Alejandro-Isidoro Pérez-Cabeza & Jose Manuel García-Pinilla. (2022) Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions. Expert Opinion on Pharmacotherapy 23:17, pages 1941-1955.
Read now
Read now
Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Mondher Toumi & Aurélie Millier. (2020) Use of real-world evidence in meta-analyses and cost-effectiveness models. Journal of Medical Economics 23:10, pages 1053-1060.
Read now
Read now
Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Aurélie Millier, Jean Tardu & Mondher Toumi. (2020) Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK. Journal of Market Access & Health Policy 8:1.
Read now
Read now
Jean-Baptiste Briere, Olivia Wu, Kevin Bowrin, Aurélie Millier, Mondher Toumi, Vanessa Taieb, Pierre Levy & Craig I. Coleman. (2019) Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation . Current Medical Research and Opinion 35:11, pages 1867-1872.
Read now
Read now
Jean-Baptiste Briere, Kevin Bowrin, Aurélie Millier, Mondher Toumi, Piotr Wojciechowski & Vanessa Taieb. (2019) Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation. Journal of Medical Economics 22:8, pages 760-765.
Read now
Read now
Articles from other publishers (25)
Arvin Radfar Akhavan, Alex O’Brien-Lambert, Nick Postiglione, Anneliese M. SchleyerMarie Vrablik & M. Kennedy Hall. (2023) Impact of an Institutional Clinical Pathway on Emergency Physicians’ Stated Preferences in Treating Patients with Low-Risk Pulmonary Embolism. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 22:4, pages 120-123.
Crossref
Crossref
Brett D. Atwater, Jennifer D. Guo, Allison Keshishian, Rachel Delinger, Cristina Russ, Lisa Rosenblatt, Jenny Jiang, Huseyin Yuce & Mauricio Ferri. (2023) Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation. Journal of Thrombosis and Thrombolysis.
Crossref
Crossref
Lucia Victoria Bortman, Florencia Mitchell, Sofia Naveiro, Juana Pérez Morales, Claudio Daniel Gonzalez, Guillermo Di Girolamo & Mariano Anibal Giorgi. (2023) Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation. The Journal of Clinical Pharmacology 63:4, pages 383-396.
Crossref
Crossref
Jeffrey S. Berger, Veronica Ashton, François Laliberté, Guillaume Germain, Brahim Bookhart, Dominique Lejeune, Julien Boudreau, Patrick Lefebvre & Matthew R. Weir. (2023) Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population. Advances in Therapy 40:3, pages 1224-1241.
Crossref
Crossref
Samuel Lévy, Gerhard Steinbeck, Luca Santini, Michael Nabauer, Diego Penela Maceda, Bharat K. Kantharia, Sanjeev Saksena & Riccardo Cappato. (2022) Management of atrial fibrillation: two decades of progress — a scientific statement from the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology 65:1, pages 287-326.
Crossref
Crossref
Ronny Alcalai, Adi Butnaru, Gil Moravsky, Oren Yagel, Razek Rashad, Mahsati Ibrahimli, David Planer, Offer Amir, Gabby Elbaz-Greener & David Leibowitz. (2022) Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial. European Heart Journal - Cardiovascular Pharmacotherapy 8:7, pages 660-667.
Crossref
Crossref
Phannita Wattanaruengchai, Surakit Nathisuwan, Khemajira Karaketklang, Wanwarang Wongcharoen, Arintaya Phrommintikul & Gregory Y. H. Lip. (2021) Comparison of the HAS‐BLED versus ORBIT scores in predicting major bleeding among Asians receiving direct‐acting oral anticoagulants. British Journal of Clinical Pharmacology 88:5, pages 2203-2212.
Crossref
Crossref
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi & Jean-Baptiste Briere. (2022) Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain. PLOS ONE 17:4, pages e0266658.
Crossref
Crossref
Jose Miguel Calderon, Fernando Martinez, Antonio Fernandez, Inmaculada Sauri, Javier Diaz, Ruth Uso, Jose Luis Trillo, Josep Redon & Maria Jose Forner. (2022) Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status. Scientific Reports 12:1.
Crossref
Crossref
Adane Teshome Kefale, Gregory M. Peterson, Woldesellassie M. Bezabhe & Luke R. Bereznicki. (2021) Switching of oral anticoagulants in patients with nonvalvular atrial fibrillation: A narrative review. British Journal of Clinical Pharmacology 88:2, pages 514-534.
Crossref
Crossref
Jose Miguel Calderon, Fernando Martinez, Javier Diaz, Antonio Fernandez, Inmaculada Sauri, Ruth Uso, Jose Luis Trillo, Sara Vela, Carlos Bea, Josep Redon & Maria Jose Forner. (2022) Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Mario Gaio, Carmen Ferrajolo, Alessia Zinzi, Consiglia Riccardi, Pasquale Di Filippo, Ludovica Carangelo, Gorizio Pieretti, Francesco Rossi, Giovanni Francesco Nicoletti & Annalisa Capuano. (2021) Association of Direct Oral Anticoagulants (DOACs) and Warfarin With Haemorrhagic Risk by Applying Correspondence Analysis to Data From the Italian Pharmacovigilance Database – A Case Study. Frontiers in Pharmacology 12.
Crossref
Crossref
Lamiae Grimaldi-Bensouda, Jean-Yves Le HeuzeyJean FerrièresDidier LeysJean-Marc DavyMikel MartinezOlivia DiallaDidier SmadjaNorbert NighoghossianJacques Benichou, Clementine NordonEmmanuel TouzéLucien Abenhaim. (2021) Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors. Stroke 52:10, pages 3121-3131.
Crossref
Crossref
A. John Camm & Dan Atar. (2021) Use of Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention across the Stroke Spectrum: Progress and Prospects. Thrombosis and Haemostasis 121:06, pages 716-730.
Crossref
Crossref
M. Rosa Dalmau Llorca, Carina Aguilar Martín, Noèlia Carrasco-Querol, Zojaina Hernández Rojas, Emma Forcadell Drago, Dolores Rodríguez Cumplido, Elisabet Castro Blanco, Alessandra Queiroga Gonçalves & José Fernández-Sáez. (2021) Anticoagulation Control with Acenocoumarol or Warfarin in Non-Valvular Atrial Fibrillation in Primary Care (Fantas-TIC Study). International Journal of Environmental Research and Public Health 18:11, pages 5700.
Crossref
Crossref
Domenico D’Amario, Mattia Galli, Francesco Canonico, Attilio Restivo, Alessandra Arcudi, Roberto Scacciavillani, Luigi Cappannoli, Maria Elena Riccioni, Maria Giuseppina Annetta, Gaetano Di Stefano, Carlo Piccinni, Rocco Vergallo, Rocco Antonio Montone, Antonio Maria Leone, Giampaolo Niccoli, Mario Sabatelli, Massimo Antonelli, Felicita Andreotti, Raimondo De Cristofaro & Filippo Crea. (2021) ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study. Journal of Cardiovascular Medicine 22:3, pages 175-179.
Crossref
Crossref
Giulio Francesco Romiti, Bernadette Corica & Marco Proietti. (2021) A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: a 10-year-long story. Future Cardiology 17:2, pages 215-226.
Crossref
Crossref
Hans-Christoph Diener, Jens Fiehler, Karl Georg Häusler, Joji B. Kuramatsu, Waltraud Pfeilschifter, Jan Christoph Purrucker, Renate B. Schnabel, Jochen A. Sembill, Roland Veltkamp & Christian Weimar. (2021) Neues beim Schlaganfall – Teil 1: Akuttherapie. Neurologie up2date 4:01, pages 23-45.
Crossref
Crossref
Despoina-Rafailia Benetou, Charalampos Varlamos, Dionysios Ktenas, Ioannis Tsiafoutis, Michael Koutouzis, Theodora Bampali, Christos Mantis, John Zarifis, Emmanouil Skalidis, Dionysios Aravantinos, Dimitrios Varvarousis, Ioannis Lianos, John Kanakakis, Evangelos Pisimisis, Antonios Ziakas, Periklis Davlouros & Dimitrios Alexopoulos. (2020) Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry. Cardiovascular Drugs and Therapy 35:1, pages 11-20.
Crossref
Crossref
Jaap Seelig, Martin E.W. Hemels, Olivier Xhaët, Maarten C.M. Bongaerts, Axel de Wolf, Björn E. Groenemeijer, Alex Heyse, Pieter Hoogslag, Joeri Voet, Jean‐Paul R. Herrman, Geert Vervoort, Walter Hermans, Bart Wollaert, Lucas V.A. Boersma, Kurt Hermans, Andreas Lucassen, Stefan Verstraete, Henk J. Adriaansen, Georges H. Mairesse, Willem F. Terpstra, Dirk Faes, Mathijs Pieterse, Saverio Virdone, Freek W.A. Verheugt, Frank Cools & Hugo ten Cate. (2020) Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry. Journal of Thrombosis and Haemostasis 18:12, pages 3280-3288.
Crossref
Crossref
Wen Jun Tiew, Vivien LX Wong, Vern Hsen Tan, Yong Chuan Tan & Elena MS Lee. (2020) A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation— A Single-centre Retrospective Cohort Study in Singapore. Annals of the Academy of Medicine, Singapore 49:11, pages 838-847.
Crossref
Crossref
Shun Kohsaka, Jun Katada, Kumiko Saito, Aaron Jenkins, Benjamin Li, Jack Mardekian & Yasuo Terayama. (2020) Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data. Open Heart 7:1, pages e001232.
Crossref
Crossref
Kevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, Craig Coleman, Aurélie Millier, Mondher Toumi, Emilie Clay & Pierre Levy. (2020) Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France. PLOS ONE 15:1, pages e0225301.
Crossref
Crossref
J. Seelig & M. E. W. Hemels. (2019) Adherence to anticoagulation: an ongoing challenge. Netherlands Heart Journal 27:12, pages 594-595.
Crossref
Crossref
Sreeram V Ramagopalan, Mihail Samnaliev, Sharada Weir, Cormac J Sammon, Robert Carroll & Raza Alikhan. (2019) Costs of gastrointestinal bleeding events in atrial fibrillation: a UK Clinical Practice Research Datalink study. Future Cardiology 15:5, pages 367-375.
Crossref
Crossref